Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Puran Chen

Showing results (21-30 of 43) with videos related to

Pageof 5
Sort By:
Haematologica|August 30, 2023
Systemic and mucosal adaptive immunity to SARS-CoV-2 during the Omicron wave in patients with chronic lymphocytic leukemiaHanna M Ingelman-Sundberg, Lisa Blixt, David Wullimann, et al.
Nature Medicine|January 18, 2022
Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variantYu Gao, Curtis Cai, Alba Grifoni, et al.
The Journal of Allergy and Clinical Immunology|September 28, 2016
Human lung natural killer cells are predominantly comprised of highly differentiated hypofunctional CD69<sup>-</sup>CD56<sup>dim</sup> cellsNicole Marquardt, Eliisa Kekäläinen, Puran Chen, et al.
Molecular Medicine (Cambridge, Mass.)|May 13, 2022
MAIT cell compartment characteristics are associated with the immune response magnitude to the BNT162b2 mRNA anti-SARS-CoV-2 vaccineCaroline Boulouis, Tobias Kammann, Angelica Cuapio, et al.
Ebiomedicine|July 15, 2023
Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a one-year follow-up of the prospective clinical trial COVAXIDPuran Chen, Peter Bergman, Ola Blennow, et al.
Plos One|December 29, 2023
Anakinra or tocilizumab in patients admitted to hospital with severe covid-19 at high risk of deterioration (IMMCoVA): A randomized, controlled, open-label trialJonas Sundén-Cullberg, Puran Chen, Henrike Häbel, et al.
Ebiomedicine|October 12, 2024
Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a two-year follow-up of the prospective clinical trial COVAXIDPuran Chen, Peter Bergman, Ola Blennow, et al.
Ebiomedicine|May 9, 2026
Three-year follow-up of the COVAXID trial: real-world assessment of SARS-CoV-2 mRNA vaccine immunogenicity in immunocompromised individuals highlights increasing roles of hybrid and passive immunityPuran Chen, Peter Bergman, Ola Blennow, et al.
Mbio|October 13, 2025
Alpha-toxin-elicited CX<sub>3</sub>CL1 release in <i>Staphylococcus aureus</i> pneumonia impairs bactericidal function of human monocytesSrikanth Mairpady Shambat, Puran Chen, Rocky M Barilla, et al.
Clinical & Translational Immunology|July 14, 2021
SARS-CoV-2-specific humoral and cellular immunity persists through 9 months irrespective of COVID-19 severity at hospitalisationJohn Tyler Sandberg, Renata Varnaitė, Wanda Christ, et al.
Pageof 5

Showing results (21-30 of 43) with videos related to

Sort By:
Pageof 5
Haematologica|August 30, 2023
Systemic and mucosal adaptive immunity to SARS-CoV-2 during the Omicron wave in patients with chronic lymphocytic leukemiaHanna M Ingelman-Sundberg, Lisa Blixt, David Wullimann, et al.
Nature Medicine|January 18, 2022
Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variantYu Gao, Curtis Cai, Alba Grifoni, et al.
The Journal of Allergy and Clinical Immunology|September 28, 2016
Human lung natural killer cells are predominantly comprised of highly differentiated hypofunctional CD69<sup>-</sup>CD56<sup>dim</sup> cellsNicole Marquardt, Eliisa Kekäläinen, Puran Chen, et al.
Molecular Medicine (Cambridge, Mass.)|May 13, 2022
MAIT cell compartment characteristics are associated with the immune response magnitude to the BNT162b2 mRNA anti-SARS-CoV-2 vaccineCaroline Boulouis, Tobias Kammann, Angelica Cuapio, et al.
Ebiomedicine|July 15, 2023
Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a one-year follow-up of the prospective clinical trial COVAXIDPuran Chen, Peter Bergman, Ola Blennow, et al.
Plos One|December 29, 2023
Anakinra or tocilizumab in patients admitted to hospital with severe covid-19 at high risk of deterioration (IMMCoVA): A randomized, controlled, open-label trialJonas Sundén-Cullberg, Puran Chen, Henrike Häbel, et al.
Ebiomedicine|October 12, 2024
Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a two-year follow-up of the prospective clinical trial COVAXIDPuran Chen, Peter Bergman, Ola Blennow, et al.
Ebiomedicine|May 9, 2026
Three-year follow-up of the COVAXID trial: real-world assessment of SARS-CoV-2 mRNA vaccine immunogenicity in immunocompromised individuals highlights increasing roles of hybrid and passive immunityPuran Chen, Peter Bergman, Ola Blennow, et al.
Mbio|October 13, 2025
Alpha-toxin-elicited CX<sub>3</sub>CL1 release in <i>Staphylococcus aureus</i> pneumonia impairs bactericidal function of human monocytesSrikanth Mairpady Shambat, Puran Chen, Rocky M Barilla, et al.
Clinical & Translational Immunology|July 14, 2021
SARS-CoV-2-specific humoral and cellular immunity persists through 9 months irrespective of COVID-19 severity at hospitalisationJohn Tyler Sandberg, Renata Varnaitė, Wanda Christ, et al.
Pageof 5